Drugs / Cardiosphere-derived cells
Cardiosphere-derived cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 missed | ||||||
| Phase 1 | NCT00893360 | May 2009 → Aug 2011 | cardiac ventricle disorder, myocardial infarction | Cedars-Sinai Medical Center | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01829750 Comparator | Apr 2013 → Mar 2016 | hypoplastic left heart syndrome, univentricular heart | Okayama University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cardiosphere-derived cells | “Cardiosphere-derived cells (CDCs) reduce scarring after myocardial infarction, increase viable myocardium, and boost cardiac function in preclinical models.” PMID 22336189 ↗ Feb 20121“the preliminary results of the phase 1 trial showed that cardiosphere-derived cells (CDCs) may be effective against congenital heart failure.” PMID 28052915 ↗ Jan 2017 |
| Known as | cardiosphere-derived stem cells | “The purpose of this study is to determine whether giving cardiosphere-derived stem cells (CDCs) to patients with decreased heart function and/or a large amount of damaged...” NCT00893360 ↗ |
| Known as | CDCs | “Cardiosphere-derived cells (CDCs) reduce scarring after myocardial infarction, increase viable myocardium, and boost cardiac function in preclinical models.” PMID 22336189 ↗ Feb 20121“the preliminary results of the phase 1 trial showed that cardiosphere-derived cells (CDCs) may be effective against congenital heart failure.” PMID 28052915 ↗ Jan 2017 |
| Route | Other | “via intracoronary delivery” NCT00893360 ↗ |